DRV/r | New HIV Drugs v2

Pediatric DRV/r (pDRV/r) FAQs

This document is meant to answer some of the most common questions that surround pediatric darunavir/ritonavir 120/20mg (pDRV/r) - a new...

Pediatric DRV/r (pDRV/r) Product Profile

This product profile provides a clinical overview of the best-in-class protease inhibitor (PI) formulated in a fixed-dose combination...

Community Statements on DRV/r Use in 2L

In December 2022, 40+ community groups and an additional 45+ individuals released a community position statement calling on the global...

CHAI Simple Tool Adults & Pediatrics

Updated: Feb 15, 2023 The CHAI Simple Tool is a morbidity-based forecasting tool that quantifies ARV needs over a three year period for...

Adult DRV/r (400/50mg) FAQs for Communities and PLHIV

CHAI developed these frequently asked questions (FAQs) to lay out information for communities and PLHIV on the subject of DRV/r (400/50...

Customizable Adult DRV/r (400/50mg) Healthcare Worker Training Slides

CHAI has developed a generic training curriculum that is intended to be adapted for local contexts and their respective training plans.

Adult DRV/r (400/50mg) Clinical Action Memo

Darunavir (DRV) is a best-in-class protease inhibitor (PI) used in combination with other antiretroviral (ARV) drugs for the...

Customizable Adult DRV/r (400/50mg) Prescribing Algorithm

CHAI is pleased to share a customizable guide to assist healthcare workers with prescribing and dispensing second-line (2L) DRV/r...

CHAI DRV/r 2L Product Profile

A presentation with the latest information on DRV/r (400/50mg) and considerations for adult second line treatment optimization.

DRV/r (400/50mg) FAQs

CHAI developed these frequently asked questions (FAQs) to lay out information for national HIV programs considering the adoption and...

CHAI National Stock Status Dashboard

Keeping an adequate stock of ARVs on hand is important for multiple reasons. Too much stock, and programs run the risk of products...

CHAI Rapid Consumption Monitoring Tool

As national programs continue to rollout new generic ARVs, there is a need for routine, careful monitoring of product uptake to ensure...

HIV New Product Introduction Toolkit